Manila Times Business
RQ Bio Announces $115 Million (£85.5 Million) Series A Financing to Advance Long-Acting Antibody Programme RQB01 for Full Season Influenza Prevention
Mike Westby CEO of RQ Bio Financing led by Frazier Life Sciences with participation from new investors EQT Life Sciences, Forbion, Monograph, Wellington Management and founding investor LifeArc VenturesProceeds support clinical development of lead programme RQB01 designed to provide seasonal influenza protection with a single administrationChristian S. Schade appointed Executive ChairmanLONDON, United Kingdom, June 24, 2026 - RQ Bio, a private biotechnology company developing long-acting antibod
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Trump orders probe because gas prices not falling enough
5h ago
HKPC Leads Four Hong Kong I&T Enterprises to Paris VivaTech 2026 Leveraging Hong Kong's "Two-Way Springboard" Strategic Advantage to Accelerate Global Markets Connections
5h ago
ATLANT 3D, A*STAR IMRE and NAMIC Sign MoU to Advance AI-Driven Materials Discovery in Singapore
5h ago
TECNO Showcases Expanded EllaClaw Capabilities, Advancing Practical Agentic AI that Gets Things Done
5h ago